ES2350880T3 - Purificación de péptidos. - Google Patents
Purificación de péptidos. Download PDFInfo
- Publication number
- ES2350880T3 ES2350880T3 ES02783479T ES02783479T ES2350880T3 ES 2350880 T3 ES2350880 T3 ES 2350880T3 ES 02783479 T ES02783479 T ES 02783479T ES 02783479 T ES02783479 T ES 02783479T ES 2350880 T3 ES2350880 T3 ES 2350880T3
- Authority
- ES
- Spain
- Prior art keywords
- mixture
- peptide
- nona
- sub
- deca
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 22
- 238000000746 purification Methods 0.000 title claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 title description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000002904 solvent Substances 0.000 claims abstract description 24
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000000203 mixture Substances 0.000 claims abstract description 19
- 238000001556 precipitation Methods 0.000 claims abstract description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000011877 solvent mixture Substances 0.000 claims abstract description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 150000001875 compounds Chemical class 0.000 claims abstract description 8
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims abstract description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims abstract description 5
- 239000003960 organic solvent Substances 0.000 claims abstract description 5
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims abstract description 3
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims abstract description 3
- 235000019260 propionic acid Nutrition 0.000 claims abstract description 3
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims abstract description 3
- UAEPNZWRGJTJPN-UHFFFAOYSA-N methylcyclohexane Chemical compound CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 claims abstract 4
- GYNNXHKOJHMOHS-UHFFFAOYSA-N methyl-cycloheptane Natural products CC1CCCCCC1 GYNNXHKOJHMOHS-UHFFFAOYSA-N 0.000 claims abstract 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 20
- 229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 3
- 239000002474 gonadorelin antagonist Substances 0.000 claims description 3
- RMOUBSOVHSONPZ-UHFFFAOYSA-N Isopropyl formate Chemical compound CC(C)OC=O RMOUBSOVHSONPZ-UHFFFAOYSA-N 0.000 claims description 2
- RJUFJBKOKNCXHH-UHFFFAOYSA-N Methyl propionate Chemical compound CCC(=O)OC RJUFJBKOKNCXHH-UHFFFAOYSA-N 0.000 claims description 2
- GJRQTCIYDGXPES-UHFFFAOYSA-N iso-butyl acetate Natural products CC(C)COC(C)=O GJRQTCIYDGXPES-UHFFFAOYSA-N 0.000 claims description 2
- FGKJLKRYENPLQH-UHFFFAOYSA-M isocaproate Chemical compound CC(C)CCC([O-])=O FGKJLKRYENPLQH-UHFFFAOYSA-M 0.000 claims description 2
- OQAGVSWESNCJJT-UHFFFAOYSA-N isovaleric acid methyl ester Natural products COC(=O)CC(C)C OQAGVSWESNCJJT-UHFFFAOYSA-N 0.000 claims description 2
- 229940017219 methyl propionate Drugs 0.000 claims description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 2
- WMOVHXAZOJBABW-UHFFFAOYSA-N tert-butyl acetate Chemical compound CC(=O)OC(C)(C)C WMOVHXAZOJBABW-UHFFFAOYSA-N 0.000 claims description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 claims 2
- 235000015278 beef Nutrition 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 238000005406 washing Methods 0.000 abstract description 2
- 150000002148 esters Chemical class 0.000 abstract 2
- 125000005907 alkyl ester group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001735 carboxylic acids Chemical class 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 238000001035 drying Methods 0.000 abstract 1
- 239000000047 product Substances 0.000 description 19
- 108700012941 GNRH1 Proteins 0.000 description 4
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 108010038281 D1 peptide Proteins 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010023617 abarelix Proteins 0.000 description 1
- AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 description 1
- 229960002184 abarelix Drugs 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- RFQIWHDNNZFRBL-UHFFFAOYSA-N acetic acid;ethanol;hydrate Chemical compound O.CCO.CC(O)=O RFQIWHDNNZFRBL-UHFFFAOYSA-N 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000002434 gonadorelin derivative Substances 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/30—Extraction; Separation; Purification by precipitation
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE2001104462 | 2001-12-29 | ||
| SE0104462A SE0104462D0 (sv) | 2001-12-29 | 2001-12-29 | Peptide purifcation (Peptidrening) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2350880T3 true ES2350880T3 (es) | 2011-01-27 |
Family
ID=20286556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES02783479T Expired - Lifetime ES2350880T3 (es) | 2001-12-29 | 2002-12-23 | Purificación de péptidos. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7057014B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1468009B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4378173B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR100880828B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN1272341C (cg-RX-API-DMAC7.html) |
| AT (1) | ATE449784T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2002347550B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2471717C (cg-RX-API-DMAC7.html) |
| DE (1) | DE60234535D1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK1468009T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2350880T3 (cg-RX-API-DMAC7.html) |
| IL (2) | IL162789A0 (cg-RX-API-DMAC7.html) |
| NO (1) | NO329024B1 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ534151A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2303040C2 (cg-RX-API-DMAC7.html) |
| SE (1) | SE0104462D0 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2003055900A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200405135B (cg-RX-API-DMAC7.html) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1359722A1 (en) * | 2002-03-27 | 2003-11-05 | BRITISH TELECOMMUNICATIONS public limited company | Data streaming system and method |
| AU2006207325B2 (en) | 2005-01-21 | 2012-08-16 | Astex Therapeutics Limited | Pharmaceutical compounds |
| US8916552B2 (en) | 2006-10-12 | 2014-12-23 | Astex Therapeutics Limited | Pharmaceutical combinations |
| JP5528807B2 (ja) | 2006-10-12 | 2014-06-25 | アステックス、セラピューティックス、リミテッド | 複合薬剤 |
| US9051349B2 (en) | 2007-11-21 | 2015-06-09 | Alba Therapeutics Corporation | Larazotide acetate compositions |
| EP2062909A1 (en) * | 2007-11-21 | 2009-05-27 | SOLVAY (Société Anonyme) | Peptide production and purification process |
| US20120149868A1 (en) * | 2008-05-15 | 2012-06-14 | Novo Nordisk A/S | Purification of peptides prepared by solid phase synthesis |
| DK2417152T3 (da) * | 2009-04-10 | 2013-12-16 | Corden Pharma Colorado Inc | Fremgangsmåde til isolering af linaclotid |
| CN104837508A (zh) | 2012-12-13 | 2015-08-12 | 免疫医疗公司 | 功效改进且毒性降低的抗体与sn-38的免疫缀合物的剂量 |
| WO2015012904A2 (en) * | 2012-12-13 | 2015-01-29 | Immunomedics, Inc. | Antibody-sn-38 immunoconjugates with a cl2a linker |
| US9931417B2 (en) | 2012-12-13 | 2018-04-03 | Immunomedics, Inc. | Antibody-SN-38 immunoconjugates with a CL2A linker |
| EP3024460B1 (en) * | 2013-07-23 | 2020-07-22 | Immunomedics, Inc. | Method for producing antibody-sn-38 immunoconjugates with a cl2a linker |
| CN109310385A (zh) | 2016-04-27 | 2019-02-05 | 免疫医疗公司 | 抗trop-2-sn-38抗体药物缀合物用于检查点抑制剂复发/难治的肿瘤的疗法的功效 |
| CA3050332A1 (en) | 2017-03-27 | 2018-10-04 | Immunomedics, Inc. | Treatment of trop-2 expressing triple negative breast cancer with sacituzumab govitecan and a rad51 inhibitor |
| WO2018187074A1 (en) | 2017-04-03 | 2018-10-11 | Immunomedics, Inc. | Subcutaneous administration of antibody-drug conjugates for cancer therapy |
| CN113952944B (zh) * | 2021-12-23 | 2022-03-29 | 浙江湃肽生物有限公司深圳分公司 | 一种纯化九肽-1的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8317697D0 (en) * | 1983-06-29 | 1983-08-03 | Shell Int Research | Dissolution of peptides in non-aqueous and mixed non-aqueous/aqueous solvents |
| DE4001238A1 (de) * | 1990-01-18 | 1991-07-25 | Basf Ag | Verfahren zur anreicherung bzw. reinigung von biomolekuelen |
| DE19544212A1 (de) * | 1995-11-28 | 1997-06-05 | Asta Medica Ag | Neue LH-RH-Antagonisten mit verbesserter Wirkung |
| DE19813849A1 (de) * | 1998-03-27 | 1999-09-30 | Degussa | Verfahren zur einstufigen Umsalzung und Aufreinigung von Oligopeptiden |
| EP0998940A1 (en) * | 1998-09-30 | 2000-05-10 | Laboratoire Theramex | Pharmaceutical compositions based on alpha-cyclodextrin for the oral administration of LH-RH analogues |
| DE19911771B4 (de) * | 1999-03-17 | 2006-03-30 | Zentaris Gmbh | LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung |
-
2001
- 2001-12-29 SE SE0104462A patent/SE0104462D0/xx unknown
-
2002
- 2002-12-23 CN CNB028283481A patent/CN1272341C/zh not_active Expired - Fee Related
- 2002-12-23 DK DK02783479.5T patent/DK1468009T3/da active
- 2002-12-23 NZ NZ534151A patent/NZ534151A/en not_active IP Right Cessation
- 2002-12-23 JP JP2003556430A patent/JP4378173B2/ja not_active Expired - Fee Related
- 2002-12-23 KR KR1020047010363A patent/KR100880828B1/ko not_active Expired - Fee Related
- 2002-12-23 US US10/500,302 patent/US7057014B2/en not_active Expired - Fee Related
- 2002-12-23 CA CA2471717A patent/CA2471717C/en not_active Expired - Fee Related
- 2002-12-23 ES ES02783479T patent/ES2350880T3/es not_active Expired - Lifetime
- 2002-12-23 AT AT02783479T patent/ATE449784T1/de not_active IP Right Cessation
- 2002-12-23 DE DE60234535T patent/DE60234535D1/de not_active Expired - Lifetime
- 2002-12-23 IL IL16278902A patent/IL162789A0/xx unknown
- 2002-12-23 AU AU2002347550A patent/AU2002347550B2/en not_active Ceased
- 2002-12-23 WO PCT/IB2002/005581 patent/WO2003055900A1/en not_active Ceased
- 2002-12-23 RU RU2004119965/04A patent/RU2303040C2/ru not_active IP Right Cessation
- 2002-12-23 EP EP02783479A patent/EP1468009B1/en not_active Expired - Lifetime
-
2004
- 2004-06-28 ZA ZA2004/05135A patent/ZA200405135B/en unknown
- 2004-06-29 IL IL162789A patent/IL162789A/en not_active IP Right Cessation
- 2004-07-16 NO NO20043046A patent/NO329024B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2471717C (en) | 2013-06-18 |
| KR20040090966A (ko) | 2004-10-27 |
| NO329024B1 (no) | 2010-08-02 |
| ZA200405135B (en) | 2005-08-31 |
| HK1076112A1 (en) | 2006-01-06 |
| RU2303040C2 (ru) | 2007-07-20 |
| EP1468009B1 (en) | 2009-11-25 |
| DE60234535D1 (de) | 2010-01-07 |
| JP2005515217A (ja) | 2005-05-26 |
| RU2004119965A (ru) | 2006-01-10 |
| AU2002347550A1 (en) | 2003-07-15 |
| AU2002347550B2 (en) | 2008-01-03 |
| US7057014B2 (en) | 2006-06-06 |
| EP1468009A1 (en) | 2004-10-20 |
| CA2471717A1 (en) | 2003-07-10 |
| WO2003055900A1 (en) | 2003-07-10 |
| CN1272341C (zh) | 2006-08-30 |
| IL162789A0 (en) | 2005-11-20 |
| DK1468009T3 (da) | 2010-04-06 |
| CN1625561A (zh) | 2005-06-08 |
| KR100880828B1 (ko) | 2009-01-30 |
| NO20043046L (no) | 2004-08-30 |
| ATE449784T1 (de) | 2009-12-15 |
| IL162789A (en) | 2010-04-29 |
| JP4378173B2 (ja) | 2009-12-02 |
| US20060014694A1 (en) | 2006-01-19 |
| SE0104462D0 (sv) | 2001-12-29 |
| NZ534151A (en) | 2007-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2350880T3 (es) | Purificación de péptidos. | |
| JP3266311B2 (ja) | 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤 | |
| KR100360129B1 (ko) | 리포펩티드유도체,이의제조방법및이를포함하는약제학적조성물 | |
| JP6975433B2 (ja) | ポリミキシン誘導体及びその製造方法と応用 | |
| CA2852468A1 (en) | Peptidomimetic macrocyles | |
| JP3453144B2 (ja) | １‐デアミノ‐８‐ｄ‐アルギニン・バソプレッシンの製造法 | |
| ES2596103T3 (es) | Purificación de compuestos intermedios de caspofungina | |
| KR0184604B1 (ko) | 신규한 폴리펩타이드 및 그것으로 제조한 항-hiv약제 | |
| CN117486994A (zh) | 一种抗菌订书肽及其制备方法和应用 | |
| JP2005515217A5 (cg-RX-API-DMAC7.html) | ||
| CH637111A5 (fr) | Composes polypeptidiques a activite thymique ou antagoniste et leurs procedes de synthese. | |
| Stewart | The p-methoxybenzyl ester group in peptide synthesis | |
| KR0171614B1 (ko) | 혈관활성 바소토신 유도체 | |
| FR2686343A1 (fr) | Nouveaux derives pseudopeptidiques a activite antagoniste de la bradykinine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. | |
| EP1225918A2 (en) | Conjugates useful in the treatment of prostate cancer | |
| KR102584556B1 (ko) | 자가조립 펩타이드 분자를 포함하는 접합체 및 그의 용도 | |
| FR2692581A1 (fr) | Nouveaux dérivés peptidiques à activité antagoniste de la bradykinine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. | |
| JPS62501212A (ja) | サブスタンスｐ及びそのフラグメントの誘導体 | |
| ES2355280T3 (es) | Procedimientos de purificación de compuestos de tipo equinocandina. | |
| Hruby et al. | The Design and Synthesis of Long-Acting Oxytocin Antagonists Substituted in Positions 2, 7, and 8 | |
| HK1076112B (en) | Peptide purification | |
| BE675694A (cg-RX-API-DMAC7.html) | ||
| HK1154860B (en) | Indolesulfonyl protecting groups for protection of guanidino and amino groups | |
| HK1154860A1 (en) | Indolesulfonyl protecting groups for protection of guanidino and amino groups |